Bharat H Joshi
Overview
Explore the profile of Bharat H Joshi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
1173
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Leland P, Degheidy H, Lea A, Bauer S, Puri R, Joshi B
Clin Transl Med
. 2024 Apr;
14(5):e1664.
PMID: 38685487
Background: Previously, we discovered that human solid tumours, but not normal human tissues, preferentially overexpress interleukin-13Receptor alpha2, a high binding receptor for IL-13. To develop novel anti-cancer approaches, we constructed...
2.
Leland P, Kumar D, Nimmagadda S, Bauer S, Puri R, Joshi B
J Transl Med
. 2023 Sep;
21(1):636.
PMID: 37726828
No abstract available.
3.
Leland P, Kumar D, Nimmagadda S, Bauer S, Puri R, Joshi B
J Transl Med
. 2023 Jun;
21(1):367.
PMID: 37286997
Background: Chimeric antigen receptor (CAR) T cell therapy is an exciting cell-based cancer immunotherapy. Unfortunately, CAR-T cell therapy is associated with serious toxicities such as cytokine release syndrome (CRS) and...
4.
Sato Y, Vatsan R, Joshi B, Husain S, Puri R
Curr Mol Med
. 2023 Mar;
24(6):758-770.
PMID: 36999709
Background: Genetically altered recombinant poxviruses hold great therapeutic promise in animal models of cancer. Poxviruses can induce effective cellmediated immune responses against tumor-associated antigens. Preventive and therapeutic vaccination with a...
5.
Leland P, Kumar D, Nimaggada S, Bauer S, Puri R, Joshi B
Res Sq
. 2023 Jan;
PMID: 36711796
Background Chimeric antigen receptor (CAR) T cell therapy is an exciting cell-based cancer immunotherapy. Unfortunately, CAR-T cell therapy is associated with serious toxicities such as cytokine release syndrome (CRS) and...
6.
Knudson K, Hwang S, McCann M, Joshi B, Husain S, Puri R
Front Immunol
. 2022 Apr;
13:878365.
PMID: 35464460
Interleukin-13 receptor subunit alpha-2 (IL-13Rα2, CD213A), a high-affinity membrane receptor of the anti-inflammatory Th2 cytokine IL-13, is overexpressed in a variety of solid tumors and is correlated with poor prognosis...
7.
Fujisawa T, Joshi B, Takahashi S, Takasaki Y, Suzuki A, Ito K, et al.
Diagnostics (Basel)
. 2021 Jul;
11(7).
PMID: 34201539
IL-13Rα2 is a high-affinity binding protein for its ligand IL-13 and a cancer-testis antigen as it is expressed in the testis. IL-13Rα2 is highly expressed in various cancers, including pancreatic...
8.
Fujisawa T, Shimamura T, Goto K, Nakagawa R, Muroyama R, Ino Y, et al.
Cancers (Basel)
. 2020 May;
12(5).
PMID: 32443847
Perineural invasion (PNI) is one of the major pathological characteristics of pancreatic ductal adeno-carcinoma (PDAC), which is mediated by invading cancer cells into nerve cells. Herein, we identify the overexpression...
9.
Suzuki A, Puri S, Leland P, Puri A, Moudgil T, Fox B, et al.
PLoS One
. 2019 May;
14(5):e0217131.
PMID: 31120964
Pyruvate kinase M2 (PKM2) is an alternatively spliced variant, which mediates the conversion of glucose to lactate in cancer cells under normoxic conditions, known as the Warburg effect. Previously, we...
10.
Bhardwaj R, Suzuki A, Leland P, Joshi B, Puri R
J Transl Med
. 2018 Dec;
16(1):369.
PMID: 30572904
Background: Previously, we have demonstrated that Interleukin 13 receptor alpha 2 (IL-13Rα2) is overexpressed in approximate 78% Glioblastoma multiforme (GBM) samples. We have also demonstrated that IL-13Rα2 can serve as...